Date: 2015-06-01
Type of information: Presentation of results at a congress
phase: 3
Announcement: presentation of results at the American Society of Clinical Oncology (ASCO) annual meeting, in Chicago
Company: Boston Biomedical (USA - MA)
Product: napabucasin (BBI608)
Action
mechanism: cancer cell stemness inhibitor. Napabucasin is an orally-administered investigational agent designed to inhibit cancer stemness pathways by targeting STAT3. It blocks cancer stem cell renewal and survival by suppressing stemness pathways, including STAT3, ?-catenin and immune checkpoint gene expression. Napabucasin is currently being investigated in three Phase III studies in advanced gastric and GEJ , colorectal ) and lung cancer. It is also being investigated in earlier phases in multiple solid and hematologic malignancies, including tumors of the liver, pancreas and brain.
Disease: gastric cancer, gastroesophageal junction cancer
Therapeutic area: Cancer - Oncology
Country: Australia, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Estonia, France, Germany, Hungary, Israel, Italy, Japan, Republic of Korea, Lithuania, Poland, Romania, Russian Federation, Spain, UK, USA
Trial
details: The purpose of this study is to find out whether it is better to receive a new drug, BBI608, in addition to paclitaxel chemotherapy or better to receive paclitaxel chemotherapy alone as second line treatment for gastric and gastroesophageal junction cancer after prior first line platinum and fluoropyrimidine based chemotherapy. (NCT02178956)
Latest
news: * On June 1, 2015, Boston Biomedical has presented clinical data on BBI608 at the 2015 American Society of Clinical Oncology (ASCO) annual meeting in Chicago. Data presented at ASCO highlight the potential of BBI608 for anti-cancer activity when used in combination with other chemotherapeutics across varying advanced cancers, including gastric and colorectal. Additionally, as part of the “trials in progress” program, the study protocol from the BRIGHTER study, a phase 3 clinical trial currently underway to investigate cancer stem cell pathway inhibition, has been showcased. The goal of the trial is to determine if BBI608 given together with paclitaxel as second-line therapy will extend survival compared to treatment with paclitaxel alone. Enrollment is ongoing at multiple sites in North America, Europe, Australia and Japan.
